PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach
This article was originally published in The Tan Sheet
Executive Summary
Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.
You may also be interested in...
Zephrex-D Efficacy Claim Passes NAD Review After Nexafed Firm Objects
NAD says that Westport Pharmaceuticals supported claims for Zephrex-D’s rate of relief and efficacy challenged by Acura Pharmaceuticals, manufacturer of Nexafed, another nonprescription PSE drug formulated to prevent extraction of the ingredient.
Nexafed Gains Rite Aid Sales, But Stumbles In Extraction-Proof PSE Tests
As Nexafed distribution picks up momentum, Acura hits a setback in developing a 100% extraction-resistant formulation of its PSE decongestant. Rite Aid, the first national drug store chain to carry Nexafed, is selling only tamper-deterrent, single-ingredient PSE formulations in West Virginia and will consider making the change in other states.
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect